Nova looks like the cleaner setup this week
Nova is the better setup this week because the latest quarter already confirmed the core story. Q1 delivered record revenue of $235.3 million, up 6% QoQ and 10% YoY; GAAP net income reached $69.3 million, or $2.04 EPS; and non-GAAP net income hit $80.3 million, or $2.33 EPS. That makes the next report more about verification than discovery.
Why the bar is high
This was not a one-segment beat. Nova reported strong demand for advanced DRAM, along with record sales of its Metrion and AncoScene platforms. Management also said service revenue and multiple product lines all reached all-time highs, which suggests broader execution rather than a temporary spike.
Why Nova still has portfolio appeal
Nova offers a more focused way to participate in semiconductor capex through metrology and process control, rather than as a broad AI beta trade improved yield management and process control. If demand stays firm and product adoption continues, the business still looks like a credible quality-growth holding heading into the next data point.
Nova's premium multiple still needs execution to support it
A rich multiple is only dangerous if the business underneath it starts to slow. Nova was listed at 48.8x forward P/E in the source material, which is not cheap. But the recent quarter still supports the growth case: gross margin held at 57.7% gross margin, and management highlighted a new facility in Asia, expected operational by end of 2026 to support demand and costs.
What has to keep working
The positive case still rests on breadth and margin durability. Nova has been moving with the same memory- and advanced-packaging-driven cycle as Micron, Amkor, and Allegro, but its metrology focus gives it a slightly different risk profile than pure memory exposure. Recent results were broad-based, with Metrion and AncoScene and service revenue all posting record levels. That does not remove valuation risk, but it does show why investors are still willing to pay up.
What to watch next
The cleaner entry remains before another verification point, not after expectations have already been reinforced by a strong print. For this week, that means watching whether guidance and commentary continue to show breadth across products, services, and customer segments.
Teradyne has the stronger AI story, but the stock looks crowded
Teradyne's operating trend is hard to argue with. The company reported Q1 revenue of $1,282 million, up 87% year over year, and said approximately 70% of revenue tied to AI-related demand. The business story is clearly working.
The issue for new buyers is the stock setup. Teradyne has already surged 66% year to date, which leaves less room for even a small miss. That risk matters because investor commentary has also pointed to lumpy ordering as AI infrastructure spending continues to develop. In other words, the business may remain strong while the stock still struggles if expectations prove too high.
Entegris's problem is weaker growth durability
Entegris is a different kind of risk. Over the last two years, sales have declined 6.1% annually, and the same source says Wall Street estimates imply only tepid growth of 2.6% over the next 12 months. That is a tougher backdrop for a stock investors are expected to buy for future re-rating.
That does not make Entegris a broken business. It is still profitable, with a 15.5% trailing GAAP operating margin. But profitability alone may not be enough if demand stays soft and the growth path remains limited.
Portfolio action: favor Nova, stay selective on Teradyne, and avoid adding to Entegris
For this week, the cleaner move is to stay with the business showing the broadest execution. Nova still has the strongest combination of verified results and near-term visibility, with management reporting service revenue and multiple product lines all reached all-time highs and guiding second-quarter revenue to $245 million to $255 million.
Teradyne still deserves respect, but the stock looks more like a satellite position than a fresh core buy. The AI story is real, with approximately 70% of revenue tied to AI-related demand, yet the shares are already up 66% year to date, and the business can still be hurt by lumpy ordering even if the long-term theme remains intact.
Entegris, by contrast, looks risky for a different reason: the growth engine does not yet look strong enough to carry the thesis. Until sales trends improve, it is harder to justify treating the name as a priority allocation.